Revenue Dynamics YoY (Last Twelve Months): BriaCell Corp (BCTX)

Brandmark of BriaCell Corp (BCTX)

BriaCell Therapeutics (BCTX) is a crisis-resilient biotech company developing immunotherapy to combat breast cancer. The GURU.Markets system provides a chart of the company's TTM annual revenue growth rate, where 0.00 captures the value of this parameter. The business relies on strictly calibrated raw material supply chains for its trials. This innovative method prompts the body to destroy tumors without the use of toxic chemicals.

Sales Growth YoY (TTM): BriaCell (BCTX) for 02/11/2024 - 11/18/2026

BriaCell Corp (BCTX) - metric breakdowns and financial figures

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Analysis of all company metrics:BriaCell Corp (BCTX)
Mass-produced product of BriaCell Therapeutics Corp

This annual sales growth rate (rolling period) characterizes the development stage of BriaCell Therapeutics (BCTX) as a biotech startup. The indicator tracks revenue dynamics over the last 12 months, identifying systemic degradation or business expansion. Daily updates of revenue totals allow for the distinction between a random spike and a sustainable trend. For a company focused on breast cancer immunotherapy, this metric confirms the commercial viability of clinical successes. The stability of this metric determines the asset's investment attractiveness ahead of a potential acquisition.